10.05.2012

GSK Goes Hostile with $2.6 bln Human Genome Offer

GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. more25.04.2012

Amgen to Buy Turkish Drugmaker for $700 mln

U.S. biotech company Amgen is to buy Turkey's Mustafa Nevzat Pharmaceuticals, a maker of injectable generic drugs, for around $700 million in a deal underscoring Western drugmakers' thirst for emerging markets sales. more23.04.2012

Astra Fuels Biotech M&A with $1.3 bln Ardea Buy

AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector. The $32-a-share acquisition is worth $1 billion after deducting the existing cash held by Ardea, the companies said on Monday. more16.04.2012

US High Court Hears Glaxo Overtime Pay Case

The U.S. Supreme Court heard arguments on Monday on whether pharmaceutical companies must pay sales representatives overtime, a dispute that threatens the industry with billions of dollars in potential liability. more02.04.2012

Chasing Cheaper Cancer Drugs

In a nondescript suburb south of London, tucked away behind a big hospital, Paul Workman and fellow scientists are celebrating victory in the "World Cup" of cancer drug research for their work in discovering a stream of new medicines. But the win is bitter-sweet. One of the new drugs behind the coveted prize from the American Association for Cancer Research (AACR) has been deemed too costly to use in state-run British hospitals like the one next door. It is a stark example of the pricing crisis now facing cancer medicines across the globe. more22.03.2012

GSK Confirms £500 Million UK Investment Plans

GlaxoSmithKline confirmed plans on Thursday to invest more than 500 million pounds in manufacturing in Britain and said it had selected Ulverston, northern England, as the site for a previously announced biotech plant. GSK had already said it aimed to ramp up investment and bring more jobs to Britain in response to government plans to reduce the level of corporation tax applied to income from patents - a move known as a patent box. more22.03.2012

GSK, Others Vie to Buy Turkish Drugmaker

GlaxoSmithKline and rivals including Pfizer are preparing second-round bids for Turkey's Mustafa Nevzat Ilac Sanayi, a maker of injectable generic drugs, that may be worth as much as $800 million, four people familiar with the process said. The keen interest in the Istanbul-based business, also known as MN Pharmaceuticals, underscores the race by Western drugmakers to expand in emerging markets, where sales are growing much faster than in Europe and the United States. more26.01.2012

Stefan Borgas Fired as Lonza CEO

Drugs industry supplier Lonza Group ditched Chief Executive Stefan Borgas after profit last year plunged by a third and warned 2012 would pose further challenges because of a strong franc and problems at pharmaceutical firms. more22.12.2011

Pharma Asks The Money Question Earlier For New Drugs

GlaxoSmithKline executive German Pasteris is in charge of an Alzheimer's treatment that is years from reaching the market, if it ever does. But he already wants to make sure the global healthcare system will pay for it. more09.11.2011

Investments in Cincinnati on the Rise

Overseas - "It is foreign investment - the deepest form of global integra¬tion - that binds the transatlantic economy together, not trade," reported The Transatlantic Economy 2010 study published by the John Hopkins University. more